The process of changing from Mounjaro to Wegovy: What You Need to Know

Eli Lilly has made a major price adjustment for Mounjaro which will cause UK prices to match European market rates. The monthly price of Mounjaro pens will increase to £160–£320 per pen according to the dosage requirement starting 1st September 2025.

The current price change causes distress to patients because they have shown continuous treatment success. Our mission is to assist you through the transition process toward Wegovy if this medication becomes your better treatment option.

What triggered the Mounjaro price increase?

Mounjaro became available in the UK market at lower prices to provide access to patients during its initial launch. The manufacturer Eli Lilly has adjusted UK prices for Mounjaro because international pricing standards have evolved since its initial introduction.

The price change affects every UK provider who purchases products directly from the manufacturer, although Cured Pharmacy did not initiate this decision. The product quality remains the same, but the pricing structure changed for this product.

What is Wegovy?

Wegovy functions as a weekly weight loss medication through injection, which Novo Nordisk developed and the UK granted its licence. Semaglutide in Wegovy functions as a GLP-1 receptor agonist, which duplicates natural hormone signals to extend satiety and suppress appetite and improve food intake control for sustained weight reduction.

Wegovy functions as a solid weight loss substitute for Mounjaro because it targets the GLP-1 receptor despite their different receptor targets.

Category	Mounjaro	Wegovy
Active Ingredient	Tirzepatide	Semaglutide
Weight Loss Potential	~20%	~15%
Steps to Reach Max Dose	6	—
Heart Health (CVD Prevention)	—	Licensed for CVD prevention
Dosage Frequency	Once weekly	Once weekly
Price Range (UK private clinics)	£139–£254/month	£139–£254/month

What are the benefits of switching to Wegovy?

Several of our patients have made the decision to switch to Wegovy because of its advantages.

• Clinical trials have demonstrated that Wegovy produced weight loss results between 15% and 21% that match Mounjaro's performance.
• The upcoming 7.2mg Wegovy dose produced weight loss outcomes equivalent to Mounjaro in clinical studies with patients losing 21%- 25% of their body weight.
• Research indicates that Wegovy promotes fat reduction from the body while maintaining muscle mass which safeguards your metabolic rate.
• Patients who received Wegovy treatment experienced waist circumference reductions reaching up to 5.3 inches which benefits cardiovascular health.
• People taking Wegovy can benefit from cardiovascular event prevention for heart disease patients regardless of weight loss results. The medication decreases the likelihood of heart attacks and strokes by 20%.

What does switching involve?

At Cured Pharmacy we understand that medication transitions represent major changes, yet you maintain your progress. Our medical staff will evaluate your individual case to ensure a safe Mounjaro-to-Wegovy transition based on:

• How long you been on Mounjaro
• Any side effects you’ve experienced
• Your current weight loss progress
• Your dosing history and goals
• We have the capability to initiate Wegovy treatment at a higher dose because your body may already be sensitive to GLP-1 therapy and you have shown good tolerance to Mounjaro. Our treatment approach starts with a reduced dosage of Wegovy when patients have experienced nausea or bloating symptoms.

Will I need a “washout” period?

Most patients do not require an extensive washout period during their transition from Mounjaro to Wegovy.

Here’s why:

• The GLP-1 receptor is the only target for Wegovy, while Mounjaro activates both GLP-1 and GIP receptors.
• After discontinuing Mounjaro, the GIP receptor effect diminishes, which Wegovy cannot influence.
• A 7-day interval between your final Mounjaro administration and your initial Wegovy shot should minimise adverse effects like nausea or bloating.

The two medications lack receptor conflicts and maintain extended periods of presence in the body, so medical professionals can safely perform the switch when following correct clinical protocols.

Which Wegovy dose level will produce the most effective treatment for my case?

Your ideal dose will depend on:

• The degree of response you achieved from Mounjaro therapy
• The side effects you have experienced
• Your current weight
• The duration of your treatment period
• Your prescriber will evaluate your entire treatment path to identify an appropriate dose that maintains your progress while preventing the need to start from the lowest dose unless required.

Our dose guide serves as a tool for patients, yet all prescriptions receive personalised attention from our clinical team, who provide ongoing support.

Mounjaro to Wegovy Dose Comparison

Switch to Wegovy?

We need this form to understand your medical records and your entire treatment history.

The clinical team reviews your answers after submission to confirm the chosen dose matches both safety standards and effectiveness requirements for your specific case. Your treatment process will continue as normal after approval, while you can increase your dose in subsequent orders based on your response and progress.

We are present throughout your entire process to guarantee your transition remains smooth and supported.

FAQs:

Is it possible to pause Mounjaro treatment before starting with the smallest dose of Wegovy?
Yes, you can. Patients often restart their weight loss journey using 0.25 mg Wegovy because they want to begin the transition or had adverse effects with Mounjaro. The first dose you receive will be determined by your medical records and your previous tolerance of treatment. Your medical professional will provide you with personalised recommendations regarding the most suitable course of treatment.

Can I begin using Wegovy if my BMI level falls below 30?
Wegovy receives FDA approval for treating individuals with a BMI of 30 and higher or those with 27 or higher BMI and conditions including high blood pressure or PCOS or insulin resistance or sleep apnoea. We can still provide safe treatment even though your BMI has dropped below 30 after switching from Mounjaro.

Can I use Wegovy for weight maintenance purposes?
Absolutely. Wegovy functions as a secure medication which helps people maintain their weight after losing it. Our clinical team will help you achieve stabilisation on a maintenance dose to prevent weight regain after you reach your goal weight.

How long can I stay on Wegovy?
The FDA has not established any predetermined duration for Wegovy medication usage. The medication has been proven to be safe for long-term use provided patients demonstrate positive responses and receive regular monitoring. People who have weight management as a chronic condition may need to take their medication continuously because it helps both maintain their weight loss and protect their future health.

The duration of Wegovy's effectiveness after pen usage begins.
Wegovy pens require storage in either a refrigerator or at temperatures below 30°C until their 6-week expiration period. Check the expiration date and store the product according to the instructions provided.

Does the patient need a drug-free period when switching from Mounjaro to Wegovy?
Not usually. A 7-day interval exists between your final Mounjaro administration and initial Wegovy administration. Patients can transition without any extended drug-free interval because this approach eliminates side effects and creates a gentle shift between medications.

Does Wegovy provide weight loss results that match Mounjaro?
The weight loss results between Wegovy and Mounjaro differ for each person but recent clinical trials indicate equivalent outcomes especially when using the future 7.2mg Wegovy dosage available in the UK. Our team will work with you to determine your best dose of Wegovy while providing support to achieve your weight management goals if this medication suits you.

Can I switch if I’ve had side effects on Mounjaro?
Yes. A lower starting dose of Wegovy works well for patients who experienced side effects from Mounjaro treatment. Your prescriber will adjust accordingly.

References:
Wegovy® STEP trial data — Novo Nordisk
GLP-1 prescription guidance has been issued by the UK MHRA.
The Novo Nordisk company released the STEP-UP press release in 2025.